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OVERVIEW: Familial hypercholesterolemia  
•  autosomal dominant inheritance - 10 million people living with FH 
• causes high plasma levels of LDL cholesterol - regardless of their 
lifestyle & diet habits 
• 20-fold increase in premature coronary artery disease  
• 20% of myocardial infarctions under age 45 & 5% of myocardial 
infarctions under age 60 due to FH 
STANDARD OF CARE:  
• first line treatment: lifestyle & diet modifications  
• those with FH often still have high cholesterol 
• first line medications: statins 
• highest dose often doesn’t bring down LDL-C in pts with FH 
• Side Effects: muscle aches/weakness, neuro-cognitive 
impairments, liver damage, GI upset.  
Introduction
Methods
PCSK9i are effective in lowering LDL-C & cardiovascular risk in 
patients with familial hypercholesterolemia 
Strengths: 
• recruitment methods: use of healthcare professionals to recruit 
patients with existing FH diagnosis or statin intolerant patients 
• observer bias unlikely in most of the studies 
Weaknesses:  
• short study duration with no long term follow-up 
• small sample size - highest at 511 
• low diversity in terms of race & country of administration 
• no research on use in pediatric population 
Future Focus 
Discussion 
Table 1. Comparison of Results  
Results 
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• 5/6 found % of LDL-C reduction of 50% or more 
• 2/4 achieved patients LDL-C goals 
• 2/2 of the studies looking at the reduction of cardiovascular 
events found a statistically significant reduction.   
• 3/6 found at least 5% of participants had reported significant 
side effects  
• injection site reactions, GI side effects, or transaminase 
elevation.   
• 2/2 of the studies that evaluating the non-adherence due to 
cost, the cost was found to be a significant barrier for patients.
Familial hypercholesterolemia is an inherited condition that causes patients 
to have significantly increased levels of LDL cholesterol, which often leads 
to coronary artery disease.  Statin medications are typically prescribed to 
treat this condition, however these medications have adverse side effects and 
often subpar efficacy in this patient population. Evidence collected in this 
literature review yielded evidence that the use of PCSK9 inhibitors in the 
treatment of patients with familial hypercholesterolemia may be efficacious. 
Many of these studies were able to show statistically significant improvement 
of LDL-C and decrease in cardiovascular risk when compared to placebo.  In 
addition, this medication was found to be tolerated well without adverse side 
effects, most notably in patients with a statin intolerance. Although more 
research is needed, PCSK9 inhibitors seem to be efficacious compared to 
standard of care in improving LDL-C and lowering the risk of cardiovascular 













Dufour et al S NS N/A S N/A
Raal et al NS S N/A N/A N/A
Zafrir et al S S S S S
Hovingh et al S NS N/A N/A N/A
Nissen et al S S N/A NS N/A
Olry de 
Labry et al
S NS S NS S
Key: S = significant; NS = not significant 
LDL-C reduction 
S = LDL-C reduction 
of 50% or more 
  





S = 5% of participants 
reporting significant side 
effect  
NS = less than 5% 




 S = reduction in cardiovascular 
events   
NS = no reduction in 
cardiovascular events with 
PCSK9i treatment 
LDL-C goals achieved 
 S = 70% achieving LDL-C 
goals with PCSK9i medication 
  
NS = LDL-C goals not 
achieved with use of 
medication   
Non-adherence due to Cost 
 S = cost was a barrier for patients 
  
NS =  no reported cost-effectiveness 
issues 








Dufour et al I M A A M
Raal et al A M I A M
Zafrir et al N/A M A A I
Hovingh et al I A A A M
Nissen et al A A M A A
Olry de 
Labry et al
N/A A A M A
Key:  A = Adequate; M = Marginal; I = Inadequate evidence
Blinding 
A = double blind 
M = single blind 
I = no blinding or 
cohort study
Statistical power  
A = sample size > 300 
M = sample size > 100 
I = sample size > 20
Adequate treatment 
timeline  
A = 36 weeks or more 
M = 20 weeks or more  
I = less than 20 weeks 
Recruitment strategies 
A = having healthcare workers identify potential 
qualifying participants  
M = identifying/approaching participants who 
may be eligible without clinical diagnosis 
I = participants volunteering with compensation 
advertised
Bias 
A = observer bias 
highly unlikely  
M = observer bias 
unlikely  
I = observer bias likely 
Table 2. Validity assessment information used for the evidence 
A literature search was performed in October 2019 in PubMed, 
GoogleScholar, and ClinicalKey. A total of 12 articles were selected that were 
published within 5 years and included clinical trials, controlled clinical trials, 
and randomized control trials with human subjects. The study design and 
results of six of these articles were evaluated and compared. 
synergistic 
effects with other 
medications
patient 
adherence long term effects
cost 
effectiveness
 PCSK9i should be considered as a possible therapeutic treatment in the 
management of patients with familial hypercholesterolemia, especially if the 
patient is statin intolerant.  These medications are effective in lowering the 
patients LDL-C and cardiovascular risk as evidenced by the six studies 
selected for review.  Although study designs and observer bias prevents these 
results from achieving clinical significance, there is promising evidence.  
Further research into this topic is warranted to address the shortcomings of 
current studies and confirm current research findings.  In addition, studies 
including cost analysis and real world use as a therapy need to be assessed 
since cost is a big factor in patient adherence. 
Further research will hopefully demonstrate the long term effectiveness vs 
cost of the medication and its use in clinical practice as a standard treatment of 
familial hypercholesterolemia.
Conclusion
